Evidence map›Paper›PMID 35064721›Full record

Trial reportEuropean journal of heart failure2022

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.

Kirsty McDowell, Paul Welsh, Kieran F Docherty, David A Morrow, Pardeep S Jhund, Rudolf A de Boer, Eileen O'Meara, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod and 10 more

Open access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes.Clinical pharmacology : advances and applications · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 11 countries.

Kirsty McDowellBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Paul WelshBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Kieran F DochertyBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
David A MorrowCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Pardeep S JhundBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Rudolf A de BoerDepartment of Cardiology, University Medical Center and University of Groningen, Groningen, The Netherlands.
Eileen O'MearaMontreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
Silvio E InzucchiSection of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Lars KøberDepartment of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Mikhail N KosiborodSaint Luke's Mid America Heart Institute, University of Missouri, Kansas City, MO, USA.
Felipe A MartinezUniversidad Nacional de Córdoba, Córdoba, Argentina.
Piotr PonikowskiCentre for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland.
Ann HammarstedtLate Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Anna Maria LangkildeLate Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Mikaela SjöstrandLate Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Daniel LindholmLate Stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, Astrazeneca, Gothenburg, Sweden.
Scott D SolomonCardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Naveed SattarBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Marc S SabatineTIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
University of Glasgow · GBAstraZeneca (Sweden) · SEBrigham and Women's Hospital · USAstraZeneca (Spain) · ESHarvard University · USRigshospitalet · DKUniversidad Nacional de Córdoba · ARUniversité de Montréal · CAUniversity Medical Center Groningen · NLUNSW Sydney · AUWroclaw Medical University · PLYale University · US

Funding

British Heart Foundation RE/18/6/34217
6 · The paper itself

Abstract

aimsBlood uric acid (UA) levels are frequently elevated in patients with heart failure and reduced ejection fraction (HFrEF), may lead to gout and are associated with worse outcomes. Reduction in UA is desirable in HFrEF and sodium-glucose cotransporter 2 inhibitors may have this effect. We aimed to examine the association between UA and outcomes, the effect of dapagliflozin according to baseline UA level, and the effect of dapagliflozin on UA in patients with HFrEF in the DAPA-HF trial. METHODS AND

resultsThe association between UA and the primary composite outcome of cardiovascular death or worsening heart failure, its components, and all-cause mortality was examined using Cox regression analyses among 3119 patients using tertiles of UA, after adjustment for other prognostic variables. Change in UA from baseline over 12 months was also evaluated. Patients in tertile 3 (UA ≥6.8 mg/dl) versus tertile 1 (<5.4 mg/dl) were younger (66.3 ± 10.8 vs. 68 ± 10.2 years), more often male (83.1% vs. 71.5%), had lower estimated glomerular filtration rate (58.2 ± 17.4 vs. 70.6 ± 18.7 ml/min/1.73 m

conclusionUric acid remains an independent predictor of worse outcomes in a well-treated contemporary HFrEF population. Compared with placebo, dapagliflozin reduced UA and improved outcomes irrespective of UA concentration.

Indexed as

Heart FailureVentricular Dysfunction, LeftAgedBenzhydryl CompoundsFemaleGlucosidesHumansMaleMiddle AgedStroke VolumeUric AcidBenzhydryl CompoundsdapagliflozinGlucosidesUric AcidDiabetesHeart failureMortalitySodium-glucose cotransporter 2Uric acid

Identifiers

PMID35064721
PMCPMC9540869
OpenAlexW4206946749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.